Risk Analysis: ZIRAX (UK) LIMITED

1. Risk Rating: MEDIUM

While the company demonstrates reasonable financial health with positive profitability, growing net assets, and a strong cash position, significant concerns around the sustained revenue decline, potential related-party dependency, and geopolitical/sanctions risk associated with the oilfield chemicals trade and Russian-connected directors warrant a medium risk classification. The company is solvent and liquid, but the business trajectory and structural dependencies raise questions about long-term operational sustainability.

2. Key Concerns

Concern 1: Severe and Sustained Revenue Decline

Turnover has fallen from £7.1M (2021) to £4.5M (2022) to £4.3M (2023) to £2.6M (2024) — representing a 64% decline over three years. This is not a temporary fluctuation but a consistent downward trajectory. While the company remains profitable at reduced revenue levels, a business losing two-thirds of its turnover over three years faces fundamental questions about market position, customer retention, and long-term viability. The 2024 gross margin improvement (approximately 29% vs 21% in 2023) may indicate a shift toward higher-margin but lower-volume business, which could concentrate risk further.

Concern 2: Related-Party Dependency and Corporate Structure

Zirax Limited (a corporate entity) is listed as a Person with Significant Control alongside Mr Nicholas Louis, both holding >75% of shares and voting rights. This dual PSC structure strongly suggests ZIRAX (UK) LIMITED operates as a subsidiary or UK arm of a larger group. With only 2 employees and a wholesale business model, this entity likely functions as an intermediary within the group structure. The risk is that financial performance may be significantly influenced by transfer pricing arrangements, intercompany transactions, or group-level strategic decisions rather than standalone market dynamics. The debtors balance of £177k could include intercompany receivables not separately disclosed in these abbreviated accounts.

Concern 3: Geopolitical and Sanctions Risk

The company's principal activity involves "specialty chemicals based on Calcium Chloride for oilfield processes" — a sector directly connected to the oil and gas industry. Director Anna Shevchenko is listed with Russian nationality. Given the extensive UK and international sanctions regimes targeting Russian entities and individuals, particularly in the energy sector, this creates potential compliance exposure. While no disqualification orders are recorded and there is no evidence of sanctions violations, the intersection of Russian-connected directors, oilfield chemicals trading, and current geopolitical circumstances warrants heightened due diligence. Any sanctions designation of connected parties could materially impact the company's ability to trade.

3. Positive Indicators

• Strong and Improving Balance Sheet: Net assets have grown consistently from £68k (2021) to £202k (2022) to £515k (2023) to £865k (2024). The company is building equity reserves steadily.

• Healthy Liquidity Position: Cash of £1.09M represents 86% of total assets. The current ratio stands at approximately 3.1x (£1,270k / £405k), indicating a comfortable ability to meet short-term obligations. There are no long-term liabilities.

• Profitability Maintained: Despite the significant revenue decline, the company generated £350k profit after tax in 2024 (up from £313k in 2023). This demonstrates effective cost management and suggests the business model can be profitable at lower revenue levels.

• Filing Compliance: Accounts are filed and up to date with no overdue filings. The confirmation statement is current. This suggests competent administration and regulatory compliance.

• No Debt Leverage: The company carries no long-term debt and appears entirely equity-funded, reducing solvency risk considerably.

4. Due Diligence Notes

1. Related-Party Transactions: Request full details of all transactions with Zirax Limited and other group entities. The abbreviated accounts do not disclose related-party balances. Determine whether revenue is generated from arm's-length third parties or primarily from intra-group trading.

2. Parent Entity Investigation: Investigate Zirax Limited (the PSC corporate entity) — its jurisdiction of incorporation, ownership, financial health, and any potential sanctions exposure. The UK entity's viability may be contingent on the parent's circumstances.

3. Sanctions Screening: Conduct comprehensive sanctions screening on all directors, the corporate PSC, and ultimate beneficial owners. Given Ms Shevchenko's Russian nationality and the oilfield chemicals business, this is essential. Verify no OFSI, OFAC, EU, or other sanctions designations apply to connected parties.

4. Revenue Decline Root Cause: Seek management explanation for the consistent revenue decline. Is this driven by market conditions, loss of specific contracts, deliberate strategic contraction, or changes in group trading arrangements? Understanding whether the decline is expected to continue, stabilize, or reverse is critical.

5. Customer and Supplier Concentration: With £2.6M turnover and only 2 employees, understand the customer and supplier base. High concentration in either creates vulnerability. Determine if the company is essentially a pass-through entity for the parent group.

6. Debtors Quality: The £177k debtors balance should be analysed for collectability, aging, and related-party composition. With no bad debt provision apparent in these abbreviated accounts, understand the credit risk profile.

7. Operational Continuity: With only 2 employees, assess key-person dependency. The directors appear to be the entire workforce. What succession or continuity plans exist?

8. Name Change History: The company was incorporated as MINMAR (780) LIMITED and renamed to ZIRAX (UK) LIMITED within weeks (June to August 2006). This suggests it was acquired as a shelf company, which is common but worth confirming the rationale.